$EYPT News

Last published 5d ago

5d agoEYPTEyePoint Announces Participation at Upcoming Investor Conferences and Scientific MeetingsGlobeNewswireWATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
5d agoEYPTEyePoint Announces Participation at Upcoming Investor Conferences and Scientific MeetingsGlobeNewswireWATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative...
6d agoEYPTEyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswireWATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
3w agoEYPTEyePoint Announces Strategic PrioritizationGlobeNewswireWATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
3w agoEYPTEyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMDGlobeNewswire– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary endpoints in LUCIA were
1mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal
2mo agoEYPTEyePoint Announces Participation at Upcoming Investor Conferences and Scientific MeetingGlobeNewswireWATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
2mo agoEYPTEyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMDGlobeNewswire– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to
2mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
3mo agoEYPTEyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewswire– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 –– – Pivotal Phase 3 DME clinical
3mo agoEYPTEyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)GlobeNewswire– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– – Topline 56-week
3mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
4mo agoEYPTEyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science OfficerGlobeNewswireWATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
4mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
5mo agoEYPTEyePoint Announces Participation at Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
5mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
6mo agoEYPTEyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline DataGlobeNewswire– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously completed clinical
6mo agoEYPTEyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewswirePhase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 –Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients enrolled; enrollment
6mo agoEYPTEyePoint to Report First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireWATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
6mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
8mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
8mo agoEYPTEyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewswire– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell
8mo agoEYPTEyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular EdemaGlobeNewswire– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN, Mass., March 02, 2026
8mo agoEYPTEyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026GlobeNewswireWATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
8mo agoEYPTEyePoint Announces Participation at Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
8mo agoEYPTEyePoint Appoints Michael Campbell as Chief Commercial OfficerGlobeNewswire– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent
8mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
9mo agoEYPTEyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireWATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
9mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
10mo agoEYPTEyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026GlobeNewswire– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME
10mo agoEYPTEyePoint to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal
11mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases,
11mo agoEYPTEyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular DegenerationGlobeNewswire– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline
11mo agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
1y agoEYPTEyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewswire– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program consisting of two
1y agoEYPTEyePoint Announces Participation at Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
1y agoEYPTEyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025GlobeNewswireWATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
1y agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
1y agoEYPTEyePoint Announces Pricing of Public OfferingGlobeNewswireWATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
1y agoEYPTEyePoint Announces Proposed Public Offering of Common StockGlobeNewswireWATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
1y agoEYPTEyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular EdemaGlobeNewswire– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New preclinical data
1y agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
1y agoEYPTEyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
1y agoEYPTEyePoint Announces Participation at Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
1y agoEYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireWATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
1y agoEYPTEyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoEYPTEyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceGlobeNewswireWATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
1y agoEYPTEyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewswire– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient
1y agoEYPTEyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025GlobeNewswireWATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
1y agoEYPTEyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular DegenerationGlobeNewswire– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800